The Tissue Acquisition, Pathology, and Clinical Data (TAPCD) Core has several purposes, the first and foremost of which is to maintain a tissue, blood, and urine repository for the various investigators participating in this SPORE. This task involves the collection, freezing and storage of kidney cancer and paired normal kidney tissues as well as blood and urine from consenting RCC patients. As of July 2008, frozen tissue is available on 643 patients. In addition, 1088 patients have at least one blood sample and 741 patients have at least one urine sample stored in the specimen repository. The TAPCD Core is also responsible for the maintenance of a clinical database on all consenting kidney cancer patients. This database as well as the specimen tracking and secured data management systems provide an informatics link throughout the participating DF/HCC hospitals which allow for the sharing of clinical outcome data among SPORE investigators. The TAPCD Core also provides state-of-the-art histology and molecular pathology services to SPORE Investigators. These services include: routine histology, histopathological evaluation, immunohistochemistry, in situ hybridization, computer-assisted image analysis, and generation and interrogation of tissue microarrays. In addition, this Core performs tissue microdissection, and DNA and RNA preparation for molecular studies. Finally, the TAPCD Core is responsible for performing mutation and methylation analysis of the VHL gene in clear cell RCC specimens stored in the SPORE tissue bank. Finally, the TAPCD Core collaborates with the Biostatistics Core in data analysis and auditing. This arrangement facilitates the analysis of clinical data from kidney cancer patients consented to our protocols and the correlation of clinical data with results from the various laboratory assays being carried out as part of individual SPORE Projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA101942-09
Application #
8381287
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
9
Fiscal Year
2012
Total Cost
$524,585
Indirect Cost
$118,229
Name
Beth Israel Deaconess Medical Center
Department
Type
DUNS #
071723621
City
Boston
State
MA
Country
United States
Zip Code
02215
Chen, Fengju; Zhang, Yiqun; ÅženbabaoÄŸlu, Yasin et al. (2016) Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. Cell Rep 14:2476-89
Choueiri, Toni K; Fishman, Mayer N; Escudier, Bernard et al. (2016) Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clin Cancer Res :
Albiges, Laurence; Hakimi, A Ari; Xie, Wanling et al. (2016) Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Clin Oncol :
Schildberg, Frank A; Klein, Sarah R; Freeman, Gordon J et al. (2016) Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity 44:955-72
de Velasco, Guillermo; Miao, Diana; Voss, Martin H et al. (2016) Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups. Cancer Immunol Res 4:820-822
de Velasco, Guillermo; Krajewski, Katherine M; Albiges, Laurence et al. (2016) Radiologic Heterogeneity in Responses to Anti-PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma. Cancer Immunol Res 4:12-7
Gelpi-Hammerschmidt, Francisco; Tinay, Ilker; Allard, Christopher B et al. (2016) The Contemporary Incidence and Sequelae of Rhabdomyolysis Following Extirpative Renal Surgery: A Population Based Analysis. J Urol 195:399-405
Robson, Philip M; Madhuranthakam, Ananth J; Smith, Martin P et al. (2016) Volumetric Arterial Spin-labeled Perfusion Imaging of the Kidneys with a Three-dimensional Fast Spin Echo Acquisition. Acad Radiol 23:144-54
Meng, Chen; Zeleznik, Oana A; Thallinger, Gerhard G et al. (2016) Dimension reduction techniques for the integrative analysis of multi-omics data. Brief Bioinform 17:628-41
Reardon, David A; Gokhale, Prafulla C; Klein, Sarah R et al. (2016) Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res 4:124-35

Showing the most recent 10 out of 118 publications